Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer

Selective estrogen receptor modulators (SERMs), tamoxifen, and raloxifene that reduce the risk of breast cancer are limited to only estrogen receptor-positive (ER(?)) breast cancer. In addition, patient acceptance of SERMs is low due to toxicity and intolerability. New agents with improved toxicity...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Arun, Banu K., Gong, Yun, Liu, Diane, Litton, Jennifer K., Gutierrez-Barrera, Angelica M., Lee, J. Jack, Vornik, Lana, Ibrahim, Nuhad K., Cornelison, Terri, Hortobagyi, Gabriel N., Heckman-Stoddard, Brandy M., Koenig, Kimberly B., Alvarez, Ricardo R., Murray, James L., Valero, Vicente, Lippman, Scott M., Brown, Powel, Sneige, Nour
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5989315/
https://ncbi.nlm.nih.gov/pubmed/27287781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3849-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados